CXCR2 and neoplasm: A recent study that analyzed patient samples and mice with established orthotopic tumors demonstrated that patients with non-metastatic PDAC administered a CCR2 inhibitor showed a compensatory influx of C-X-C motif chemokine receptor 2 [CXCR2] + tumor-associated neutrophils (TAN), an increase that correlates with poor prognosis in PDAC [29].